MIRA Pharmaceuticals, Inc. (MIRA)
NASDAQ: MIRA · Real-Time Price · USD
0.9942
+0.0732 (7.95%)
At close: Apr 24, 2025, 4:00 PM
1.000
+0.006 (0.58%)
Pre-market: Apr 25, 2025, 5:37 AM EDT
MIRA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for MIRA Pharmaceuticals stock have an average target of 14, with a low estimate of 11 and a high estimate of 17. The average target predicts an increase of 1,308.17% from the current stock price of 0.99.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 30, 2024.
Analyst Ratings
The average analyst rating for MIRA Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|
Strong Buy | 2 | 2 | 2 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 2 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +1,609.92% | Sep 30, 2024 |
Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +1,006.42% | Aug 5, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.55
from -0.51
EPS Next Year
-0.39
from -0.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 |
---|---|---|
High | n/a | n/a |
Avg | n/a | n/a |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
EPS Forecast
EPS | 2025 | 2026 |
---|---|---|
High | -0.57 | -0.25 |
Avg | -0.55 | -0.39 |
Low | -0.53 | -0.52 |
EPS Growth
EPS Growth | 2025 | 2026 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.